Estrogens Suppress Spinal Endomorphin 2 Release in Female Rats in Phase with the Estrous Cycle.
OBJECTIVE
Male and female rats differ in their ability to utilize spinal endomorphin 2 (EM2; the predominant mu-opioid receptor ligand in spinal cord) and in the mechanisms that underlie spinal EM2 analgesic responsiveness. We investigated the relevance of spinal estrogen receptors (ERs) to the in vivo regulation of spinal EM2 release.


METHODS
ER antagonists were administered directly to the lumbosacral spinal cord of male and female rats, intrathecal perfusate was collected, and resulting changes in EM2 release were quantified using a plate-based radioimmunoassay.


RESULTS
Intrathecal application of an antagonist of either estrogen receptor-α (ERα) or the ER GPR30 failed to alter spinal EM2 release. Strikingly, however, the concomitant blockade of ERα and GPR30 enhanced spinal EM2 release. This effect was sexually dimorphic, being absent in males. Furthermore, the magnitude of the enhancement of spinal EM2 release in females was dependent upon estrous cycle stage, suggesting a relationship with circulating levels of 17β-estradiol. The rapid onset of enhanced EM2 release following intrathecal application of ERα/GPR30 antagonists (within 30-40 min) suggests mediation via ERs in the plasma membrane, not the nucleus. Notably, both ovarian and spinally synthesized estrogens are essential for membrane ER regulation of spinal EM2 release.


CONCLUSIONS
These findings underscore the importance of estrogens for the regulation of spinal EM2 activity and, by extension, endogenous spinal EM2 antinociception in females. Components of the spinal estrogenic mechanism(s) that suppress EM2 release could represent novel drug targets for improving utilization of endogenous spinal EM2, and thereby pain management in women.
Department of Obstetrics and Gynecology, State University of New York, Downstate Medical Center, Brooklyn, N.Y., USA.
Arjun
A
Kumar
Emiliya M
EM
Storman
Nai-Jiang
NJ
Liu
Alan R
AR
Gintzler
D000818:Animals; D052117:Benzodioxoles / Q000008:administration & dosage; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors / Q000378:metabolism*; D030762:Estrous Cycle; D005260:Female; D007278:Injections, Spinal; D008297:Male; D009842:Oligopeptides / Q000378:metabolism*; D010880:Piperidines / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage; D011804:Quinolines / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013116:Spinal Cord / Q000378:metabolism*
C524478:1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole; C568862:4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline; D052117:Benzodioxoles; D047628:Estrogen Receptor alpha; C520305:Gper1 protein, rat; D009842:Oligopeptides; D010880:Piperidines; D011720:Pyrazoles; D011804:Quinolines; D043562:Receptors, G-Protein-Coupled; C105294:endomorphin 2